文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症中更早使用抗生素的获益异质性

Heterogeneity of Benefit from Earlier Time-to-Antibiotics for Sepsis.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01
一句话结论社区起病脓毒症中,更早使用抗生素的生存获益因患者特征而异,转移性癌症和休克患者获益最大。

该观察性队列研究纳入173家医院中社区起病脓毒症且在12小时内接受抗菌药物治疗的患者,共273,255例,其中131,094例(48.0%)在3小时内接受抗生素。采用多变量泊松回归、因果森林和样条逻辑回归三种方法评估更短至抗生素时间(≤3小时 vs >3-12小时)对30天死亡率获益的异质性。结果显示,转移性癌症患者绝对死亡率降低5.0%(95%CI 4.3-5.7) vs 无癌症患者0.4%(95%CI 0.2-0.6),P<0.001;休克患者7.0%(95%CI 5.8-8.2) vs 无休克患者2.8%(95%CI 2.7-3.5),P=0.005;三个及以上器官功能障碍患者4.8%(95%CI 3.9-5.6) vs 一个功能障碍患者0.5%(95%CI 0.3-0.8),P<0.001。因果森林和样条分析均确认转移性癌症和休克与更短至抗生素时间的最大获益相关。

要点

  • 社区起病脓毒症中,转移性癌症患者更短至抗生素时间的绝对死亡率降低5.0%(95%CI 4.3-5.7),无癌症患者仅0.4%(95%CI 0.2-0.6),P<0.001。
  • 休克患者更短至抗生素时间的绝对死亡率降低7.0%(95%CI 5.8-8.2),无休克患者2.8%(95%CI 2.7-3.5),P=0.005。
  • 三个及以上器官功能障碍患者绝对死亡率降低4.8%(95%CI 3.9-5.6),一个功能障碍患者0.5%(95%CI 0.3-0.8),P<0.001。
  • 因果森林分析显示转移性癌症和休克与更短至抗生素时间的最大获益相关。
  • 样条分析确认转移性癌症和休克患者中至抗生素时间与死亡率存在差异化的非线性关联。

适用人群与场景

  • 173家医院中社区起病脓毒症住院患者,且在12小时内接受抗菌药物治疗。

研究设计与关键结果

  • 观察性队列研究,纳入173家医院中社区起病脓毒症且在12小时内接受抗菌药物治疗的患者273,255例,其中131,094例(48.0%)在3小时内接受抗生素。
  • 采用多变量泊松回归评估更短(≤3小时) vs 更长(>3-12小时)至抗生素时间对30天死亡率的条件平均处理效应。
  • 转移性癌症患者更短至抗生素时间的绝对死亡率降低5.0%(95%CI 4.3-5.7),无癌症患者降低0.4%(95%CI 0.2-0.6),P<0.001。
  • 休克患者更短至抗生素时间的绝对死亡率降低7.0%(95%CI 5.8-8.2),无休克患者降低2.8%(95%CI 2.7-3.5),P=0.005。
  • 三个及以上器官功能障碍患者更短至抗生素时间的绝对死亡率降低4.8%(95%CI 3.9-5.6),一个功能障碍患者降低0.5%(95%CI 0.3-0.8),P<0.001。
  • 因果森林分析显示转移性癌症和休克与更短至抗生素时间的最大获益相关。
  • 样条分析确认转移性癌症和休克患者中至抗生素时间与死亡率存在差异化的非线性关联。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现提示对于脓毒症患者,更短至抗生素时间在癌症和/或休克患者中尤为重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Shorter time-to-antibiotics improves survival from sepsis, particularly among patients in shock. There may be other subgroups for whom faster antibiotics are particularly beneficial.Objectives: Identify patient characteristics associated with greater benefit from shorter time-to-antibiotics.Methods: Observational cohort study of patients hospitalized with community-onset sepsis at 173 hospitals and treated with antimicrobials within 12 hours. We used three approaches to evaluate heterogeneity of benefit from shorter time-to-antibiotics: 1) conditional average treatment effects of shorter (⩽3 h) versus longer (>3-12 h) time-to-antibiotics on 30-day mortality using multivariable Poisson regression; 2) causal forest to identify characteristics associated with greatest benefit from shorter time-to-antibiotics; and 3) logistic regression with time-to-antibiotics modeled as a spline.Measurements and Main Results: Among 273,255 patients with community-onset sepsis, 131,094 (48.0%) received antibiotics within 3 hours. In Poisson models, shorter time-to-antibiotics was associated with greater absolute mortality reduction among patients with metastatic cancer (5.0% [95% confidence interval; CI: 4.3-5.7] vs. 0.4% [95% CI: 0.2-0.6] for patients without cancer, P < 0.001); patients with shock (7.0% [95% CI: 5.8-8.2%] vs. 2.8% [95% CI: 2.7-3.5%] for patients without shock, P = 0.005); and patients with more acute organ dysfunctions (4.8% [95% CI: 3.9-5.6%] for three or more dysfunctions vs. 0.5% [95% CI: 0.3-0.8] for one dysfunction, P < 0.001). In causal forest, metastatic cancer and shock were associated with greatest benefit from shorter time-to-antibiotics. Spline analysis confirmed differential nonlinear associations of time-to-antibiotics with mortality in patients with metastatic cancer and shock.Conclusions: In patients with community-onset sepsis, the mortality benefit of shorter time-to-antibiotics varied by patient characteristics. These findings suggest that shorter time-to-antibiotics for sepsis is particularly important among patients with cancer and/or shock.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Hechtman RK, Kipnis P, Cano J, et al. Heterogeneity of Benefit from Earlier Time-to-Antibiotics for Sepsis. Am J Respir Crit Care Med. 2024. PMID: 38261986. doi:10.1164/rccm.202310-1800OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。